Literature DB >> 21734077

Prevention of lymphocyte apoptosis in septic mice with cancer increases mortality.

Amy C Fox1, Elise R Breed, Zhe Liang, Andrew T Clark, Brendan R Zee-Cheng, Katherine C Chang, Jessica A Dominguez, Enjae Jung, W Michael Dunne, Eileen M Burd, Alton B Farris, David C Linehan, Craig M Coopersmith.   

Abstract

Lymphocyte apoptosis is thought to have a major role in the pathophysiology of sepsis. However, there is a disconnect between animal models of sepsis and patients with the disease, because the former use subjects that were healthy prior to the onset of infection while most patients have underlying comorbidities. The purpose of this study was to determine whether lymphocyte apoptosis prevention is effective in preventing mortality in septic mice with preexisting cancer. Mice with lymphocyte Bcl-2 overexpression (Bcl-2-Ig) and wild type (WT) mice were injected with a transplantable pancreatic adenocarcinoma cell line. Three weeks later, after development of palpable tumors, all animals received an intratracheal injection of Pseudomonas aeruginosa. Despite having decreased sepsis-induced T and B lymphocyte apoptosis, Bcl-2-Ig mice had markedly increased mortality compared with WT mice following P. aeruginosa pneumonia (85 versus 44% 7-d mortality; p = 0.004). The worsened survival in Bcl-2-Ig mice was associated with increases in Th1 cytokines TNF-α and IFN-γ in bronchoalveolar lavage fluid and decreased production of the Th2 cytokine IL-10 in stimulated splenocytes. There were no differences in tumor size or pulmonary pathology between Bcl-2-Ig and WT mice. To verify that the mortality difference was not specific to Bcl-2 overexpression, similar experiments were performed in Bim(-/-) mice. Septic Bim(-/-) mice with cancer also had increased mortality compared with septic WT mice with cancer. These data demonstrate that, despite overwhelming evidence that prevention of lymphocyte apoptosis is beneficial in septic hosts without comorbidities, the same strategy worsens survival in mice with cancer that are given pneumonia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734077      PMCID: PMC3150286          DOI: 10.4049/jimmunol.1003391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice.

Authors:  Maya Saleh; John C Mathison; Melissa K Wolinski; Steve J Bensinger; Patrick Fitzgerald; Nathalie Droin; Richard J Ulevitch; Douglas R Green; Donald W Nicholson
Journal:  Nature       Date:  2006-04-20       Impact factor: 49.962

2.  Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma.

Authors:  Udaya K Liyanage; Peter S Goedegebuure; Todd T Moore; Carsten T Viehl; Tricia A Moo-Young; Justin W Larson; Daniel M Frey; Jesmin P Ehlers; Timothy J Eberlein; David C Linehan
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

3.  Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways.

Authors:  Richard S Hotchkiss; Stephen B Osmon; Katherine C Chang; Tracey H Wagner; Craig M Coopersmith; Irene E Karl
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

Review 4.  Leukocyte apoptosis and its significance in sepsis and shock.

Authors:  Doreen E Wesche; Joanne L Lomas-Neira; Mario Perl; Chun-Shiang Chung; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2005-04-07       Impact factor: 4.962

5.  Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis.

Authors:  R S Hotchkiss; P E Swanson; C M Knudson; K C Chang; J P Cobb; D F Osborne; K M Zollner; T G Buchman; S J Korsmeyer; I E Karl
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

6.  The epidemiology of sepsis in patients with malignancy.

Authors:  Pajman A Danai; Marc Moss; David M Mannino; Greg S Martin
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

7.  Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.

Authors:  Carsten T Viehl; Todd T Moore; Udaya K Liyanage; Daniel M Frey; Jesmin P Ehlers; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal:  Ann Surg Oncol       Date:  2006-09-03       Impact factor: 5.344

8.  Local thymic caspase-9 inhibition improves survival during polymicrobial sepsis in mice.

Authors:  Caroline Oberholzer; Sven K Tschoeke; Lyle L Moldawer; Andreas Oberholzer
Journal:  J Mol Med (Berl)       Date:  2006-02-02       Impact factor: 4.599

9.  Bcl-2 inhibits ischemia-reperfusion-induced apoptosis in the intestinal epithelium of transgenic mice.

Authors:  C M Coopersmith; D O'Donnell; J I Gordon
Journal:  Am J Physiol       Date:  1999-03

10.  In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice.

Authors:  Doreen E Wesche-Soldato; Chun-Shiang Chung; Joanne Lomas-Neira; Lesley A Doughty; Stephen H Gregory; Alfred Ayala
Journal:  Blood       Date:  2005-06-07       Impact factor: 22.113

View more
  11 in total

1.  Mechanisms of methicillin-resistant Staphylococcus aureus pneumonia-induced intestinal epithelial apoptosis.

Authors:  Erin E Perrone; Enjae Jung; Elise Breed; Jessica A Dominguez; Zhe Liang; Andrew T Clark; W Michael Dunne; Eileen M Burd; Craig M Coopersmith
Journal:  Shock       Date:  2012-07       Impact factor: 3.454

2.  Murine Pancreatic Cancer Alters T Cell Activation and Apoptosis and Worsens Survival After Cecal Ligation and Puncture.

Authors:  John D Lyons; Ching-Wen Chen; Zhe Liang; Wenxiao Zhang; Deena B Chihade; Eileen M Burd; Alton B Farris; Mandy L Ford; Craig M Coopersmith
Journal:  Shock       Date:  2019-06       Impact factor: 3.454

3.  Biographical Feature: William Michael Dunne, Jr., Ph.D.

Authors:  Betty A Forbes
Journal:  J Clin Microbiol       Date:  2017-09-06       Impact factor: 5.948

Review 4.  The Gut as the Motor of Multiple Organ Dysfunction in Critical Illness.

Authors:  Nathan J Klingensmith; Craig M Coopersmith
Journal:  Crit Care Clin       Date:  2016-02-04       Impact factor: 3.598

5.  2B4 but not PD-1 blockade improves mortality in septic animals with preexisting malignancy.

Authors:  Ching-Wen Chen; Ming Xue; Wenxiao Zhang; Jianfeng Xie; Craig M Coopersmith; Mandy L Ford
Journal:  JCI Insight       Date:  2019-11-14

6.  The endogenous bacteria alter gut epithelial apoptosis and decrease mortality following Pseudomonas aeruginosa pneumonia.

Authors:  Amy C Fox; Kevin W McConnell; Benyam P Yoseph; Elise Breed; Zhe Liang; Andrew T Clark; David O'Donnell; Brendan Zee-Cheng; Enjae Jung; Jessica A Dominguez; W Michael Dunne; Eileen M Burd; Craig M Coopersmith
Journal:  Shock       Date:  2012-11       Impact factor: 3.454

7.  Mechanisms of Intestinal Barrier Dysfunction in Sepsis.

Authors:  Benyam P Yoseph; Nathan J Klingensmith; Zhe Liang; Elise R Breed; Eileen M Burd; Rohit Mittal; Jessica A Dominguez; Benjamin Petrie; Mandy L Ford; Craig M Coopersmith
Journal:  Shock       Date:  2016-07       Impact factor: 3.454

8.  Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy.

Authors:  Rohit Mittal; Maylene Wagener; Elise R Breed; Zhe Liang; Benyam P Yoseph; Eileen M Burd; Alton B Farris; Craig M Coopersmith; Mandy L Ford
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

9.  Murine Lung Cancer Increases CD4+ T Cell Apoptosis and Decreases Gut Proliferative Capacity in Sepsis.

Authors:  John D Lyons; Rohit Mittal; Katherine T Fay; Ching-Wen Chen; Zhe Liang; Lindsay M Margoles; Eileen M Burd; Alton B Farris; Mandy L Ford; Craig M Coopersmith
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

10.  TIGIT modulates sepsis-induced immune dysregulation in mice with preexisting malignancy.

Authors:  Wenxiao Zhang; Jerome C Anyalebechi; Kimberly M Ramonell; Ching-Wen Chen; Jianfeng Xie; Zhe Liang; Deena B Chihade; Shunsuke Otani; Craig M Coopersmith; Mandy L Ford
Journal:  JCI Insight       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.